Sab Biotherapeutics (SABS) closed at $3.07 on October 27, 2026, up 10.0% from the previous close, on volume of 626,028 shares (30-day average 724,504).
Data as of October 27, 2026.
SAB BIO to Participate in Chardan 10th Annual Healthcare Conference
Globe Newswire (Wed, 14-Oct 8:30 AM ET)
SAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 Diabetes
Globe Newswire (Tue, 13-Oct 8:30 AM ET)
SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress
Globe Newswire (Thu, 1-Oct 8:30 AM ET)
Globe Newswire (Tue, 22-Sep 8:30 AM ET)
SAB BIO to Participate in Upcoming Investor Conferences
Globe Newswire (Tue, 1-Sep 8:30 AM ET)
SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights
Globe Newswire (Thu, 6-Aug 7:30 AM ET)
Globe Newswire (Thu, 30-Jul 8:30 AM ET)
SAB BIO Closes $85 Million Public Offering to Propel Development of T1D Therapy
Market Chameleon (Fri, 20-Mar 7:26 AM ET)
Market Chameleon (Wed, 11-Mar 6:34 AM ET)
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
Sab Biotherapeutics trades on the NASDAQ stock market under the symbol SABS.
As of October 28, 2026, SABS stock price climbed to $3.14 with 171,345 million shares trading.
SABS has a beta of 1.02, meaning it tends to be more sensitive to market movements. SABS has a correlation of 0.04 to the broad based SPY ETF.
SABS has a market cap of $285.70 million. This is considered a Small Cap stock.
In the last 3 years, SABS traded as high as $10.50 and as low as $1.00.
The top ETF exchange traded funds that SABS belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.
SABS has underperformed the market in the last year with a return of +3.6%, while the SPY ETF gained +13.8%. In the last 3 month period, SABS fell short of the market, returning -8.7%, while SPY returned +4.7%. However, in the most recent 2 weeks SABS has outperformed the stock market by returning +17.2%, while SPY returned -0.8%.
SABS support price is $2.90 and resistance is $3.24 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SABS shares will trade within this expected range on the day.
